Figure 2.

Net monetary value increase with HBsAg, anti-HBs, anti-HBc + Vacc versus status quo for a single person screened. Heplisav vaccine. Net monetary value calculates the incremental value of the HBsAg, anti-HBs, anti-HBc + Vacc strategy compared with the status quo strategy by valuing dollars at a rate of $1 = $1 and QALYs gained at a value of 1 QALY = $100,000. Positive values indicate the HBsAg, anti-HBs, anti-HBc + Vacc strategy is preferred when compared with the status quo if a policy maker is willing to pay $100,000 per QALY gained.